Jounce Therapeutics Inc $ 3.47 0.12 (3.58%)
Volume:
141,074
Avg Vol (1m):
166,818
Market Cap $:
114.45 Mil
Enterprise Value $:
-16,460,000.00
P/E (TTM):
0.00
P/B:
1.26
| Net Current Asset Value | ||
| Tangible Book | ||
| Median P/S Value | ||
|
Price: $3.47 | ||
Manual of Stocks™ Web
Financial Strength | 5.3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 7.2 | ||
| Equity-to-Asset | 0.47 | ||
| Debt-to-Equity | 0.23 | ||
| Debt-to-EBITDA | -0.72 | ||
| Piotroski F-Score | 1 | ||
| Altman Z-Score | -0.37 | ||
| Beneish M-Score | -1.45 | ||
Profitability | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -52.94 | ||
| Net Margin % | -46.07 | ||
| ROE % | -29.02 | ||
| ROA % | -13.14 | ||
| ROC (Joel Greenblatt) % | -157.17 | ||
| 3-Year EBITDA Growth Rate | 13.6 | ||
| 3-Year EPS without NRI Growth Rate | 24 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 1.26 | ||
| PS Ratio | 1.81 | ||
| EV-to-EBIT | 0.49 | ||
| EV-to-EBITDA | 0.55 | ||
| EV-to-Revenue | -0.26 | ||
| Current Ratio | 2.03 | ||
| Quick Ratio | 2.03 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 1.28 | ||
| Price-to-Median-PS-Value | 0.44 | ||
| Earnings Yield (Greenblatt) % | 203.01 |